Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT02257424	Phase Ib/II	Dabrafenib + Hydroxychloroquine + Trametinib	Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma (BAMM)	Completed	USA	0
NCT06208124	Phase Ib/II	IMM-6-415	A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors	Recruiting	USA	0
NCT03429803	Phase I	Tovorafenib	DAY101 In Gliomas and Other Tumors	Active, not recruiting	USA	0
NCT05512208	Phase II	Defactinib + RO5126766	A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib (DURAFAK)	Recruiting	USA	0
NCT05111561	Phase I	Binimetinib + ZEN-3694	Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer	Recruiting	USA	0
NCT03973918	Phase II	Binimetinib + Encorafenib	Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG (BRAF)	Terminated	USA	0
NCT04587128	Phase II	Cetuximab Cetuximab + Irinotecan Panitumumab Irinotecan + Panitumumab	Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC	Recruiting	USA	0
NCT06507306	Phase I	KQB198 + Osimertinib KQB198	A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies	Recruiting	USA \| ITA \| FRA \| ESP	2
NCT04699188	Phase Ib/II	JDQ443 JDQ443 + TNO155 JDQ443 + Tislelizumab + TNO155 JDQ443 + Tislelizumab	Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-01)	Active, not recruiting	USA \| NLD \| ITA \| FRA \| ESP \| DNK \| DEU \| CAN \| BEL \| AUS	6
NCT06284460	Phase Ib/II	ASTX029 ASTX029 + Decitabine and Cedazuridine	Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms	Withdrawn	USA	0
NCT06194877	Phase I	BGB3245 + Panitumumab	A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers	Terminated	USA \| AUS	0
NCT03979651	Phase Ib/II	Hydroxychloroquine + Trametinib	MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma (CHLOROTRAMMEL)	Unknown status	FRA	0
NCT04249843	Phase I	BGB3245	Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors	Active, not recruiting	USA \| AUS	0
NCT05554328	Phase II	Selumetinib Olaparib + Selumetinib	Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial	Recruiting	USA	1
NCT03114319	Phase I	TNO155	Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors	Active, not recruiting	USA \| NLD \| ITA \| ESP \| CAN	4
NCT02587650	Phase II	Ceritinib Capmatinib Regorafenib Entrectinib	Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma	Terminated	USA	0
NCT02974803	Phase II	Dabrafenib + Trametinib	Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases	Terminated	CAN	0
NCT02097225	Phase I	Dabrafenib + Onalespib + Trametinib	Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Terminated	USA	0
NCT05554380	Phase II	Ipatasertib + Paclitaxel	Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial	Recruiting	USA	1
NCT03919071	Phase II	Dabrafenib + Trametinib	Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma	Active, not recruiting	USA	1
NCT05658640	Phase Ib/II	Cyclophosphamide + Cytarabine + Dexamethasone + Trametinib	HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies (HEM-iSMART D)	Recruiting	SWE \| NOR \| NLD \| ITA \| ISR \| IRL \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CHE \| BEL \| AUT	0
NCT06104488	Phase I	RO5126766	A Study of Avutometinib for People With Solid Tumor Cancers	Recruiting	USA	0
NCT04487106	Phase II	Azacitidine + Trametinib + Venetoclax	Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome	Completed	USA	0
NCT05340621	Phase Ib/II	Binimetinib + OKI-179	NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)	Completed	USA	0
NCT06326411	Phase I	NST-628	A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors (NST-628)	Recruiting	USA \| AUS	0
NCT03310541	Phase I	Capivasertib Capivasertib + Enzalutamide Capivasertib + Fulvestrant	AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations	Completed	USA	0
NCT04418167	Phase I	JSI-1187 Dabrafenib + JSI-1187	JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations	Suspended	USA	0

Profile Name	NRAS act mut
Gene Variant Detail	NRAS act mut (unknown)
Relevant Treatment Approaches

We’re improving your experience!

Molecular Profile Detail

Contact

Filtering

Sorting